Driehaus Capital Management
http://www.driehaus.com/index.cfmDriehaus Capital Management is an investment management firm serving institutional clients, high net worth individuals and mutual fund investors. The firm specializes in domestic and international equity investing through separately managed accounts and mutual funds. Driehaus Capital Management was formed in 1982.
View Older Stories View More Recent Stories
-
Annexon Announces $130 Million Private Placement Financing
-
Annexon Announces $130 Million Private Placement Financing
-
Form SC 13G Real Good Food Company, Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SC 13G MELI Kaszek Pioneer Corp Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Elevation Oncology, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SC 13G/A CHANNELADVISOR CORP Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SC 13G/A CYTOKINETICS INC Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SC 13G First Light Acquisition Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SC 13G DICE Therapeutics, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SC 13G Elevation Oncology, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SC 13G Xenon Pharmaceuticals Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Congruence Therapeutics Inc. Announces US$50 million Series A Financing to Advance Platform Targeting Diseases of Protein Misfolding
-
Precision Medicine Market Size Worth USD 126 Billion | 12.50% CAGR by 2025
-
Form SC 13G Crinetics Pharmaceutical Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically Defined Diseases
-
First Trust Launches the First Trust Multi-Manager Small Cap Opportunities ETF
-
Form SC 13G/A RumbleOn, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
DiCE Molecules Announces $60 Million Series C-1 Financing
-
Form SC 13G/A ESSA Pharma Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
-
Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
-
Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
-
Form SC 13G RumbleON, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
-
Crinetics Pharmaceuticals Announces Closing of Common Stock Offering
-
Crinetics Pharmaceuticals Announces Closing of Common Stock Offering
-
X4 Pharmaceuticals (XFOR) Announces $55.0 Million At-the-Market Private Placement Financing of Common Stock, Warrants
-
X4 Pharmaceuticals Announces $55.0 Million At-the-Market Private Placement Financing
-
Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs
-
Form SC 13G ESSA Pharma Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SC 13G CHANNELADVISOR CORP Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SC 13G CHANNELADVISOR CORP Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Form SC 13G ESSA Pharma Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Signs Agreements to Acquire Leading Digital Musculoskeletal Company, Raise $70 Million Through Private Placement
-
DarioHealth (DRIO) Announces Acquisition of Leading Digital Musculoskeletal Company Upright Technologies and $70 Million Financing
-
DarioHealth Announces Acquisition of Leading Digital Musculoskeletal Company Upright Technologies and $70 Million Financing
-
DiCE Molecules Announces $80 Million Series C Financing
-
Harris Associates L.P. Launches Oakmark Bond Fund
-
Form SC 13G/A i3 Verticals, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC
-
Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer
-
Driehaus Capital Management Expands Relationship With Northern Trust With Appointment as Fund Administrator for Driehaus Mutual Funds
-
Frequency Therapeutics Provides Business Updates and Reports Second Quarter 2020 Financial Results
-
Thrive Earlier Detection Closes $257 Million Series B Financing
-
Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors Harboring Rare Genetic Driver Alterations
-
Frequency Therapeutics (FREQ) Announces $42 Million Private Placement of Common Stock
-
Frequency Therapeutics Announces $42 Million Private Placement
-
InVitae (NVTA) to Combine with ArcherDX
-
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
-
Driehaus Capital Management Announces Launch of Driehaus Small/Mid Cap Growth Fund
-
Form SC 13G/A Telaria, Inc. Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC

